Serina Therapeutics
SER
32 hedge funds and large institutions have $4.24M invested in Serina Therapeutics in 2023 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 4 increasing their positions, 11 reducing their positions, and 2 closing their positions.
34% more capital invested
Capital invested by funds: $3.15M → $4.24M (+$1.08M)
0% more funds holding
Funds holding: 32 → 32 (0)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0% less ownership
Funds ownership: 0.36% → 0.36% (-0%)
0% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 2
64% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 11
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$7.94K |
| 2 |
SPC
Sigma Planning Corp
Ann Arbor,
Michigan
|
+$5.18K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$3.42K |
| 4 |
JP Morgan Chase
New York
|
+$1.22K |
| 5 |
BlackRock
New York
|
+$21 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$15.2K |
| 2 |
SXL
Summit X LLC
Chesterfield,
Missouri
|
-$4.56K |
| 3 |
SWIG
Strategic Wealth Investment Group
Louisville,
Kentucky
|
-$2.4K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$1.67K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
-$1.2K |
SER Hedge Fund Activity: Q2 2023 in Review
32 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Serina Therapeutics (SER) for Q2 2023, worth a combined $4.24M — up 34% from $3.15M a quarter earlier.
Fund positioning in SER was balanced in Q2 2023: 2 funds opened new positions, 2 closed out, 4 added to existing stakes and 11 trimmed.
The largest buyer was Susquehanna International Group, adding an estimated $7.94K. The largest seller was Bridgeway Capital Management, cutting an estimated $15.2K.
- 32 institutional investors held Serina Therapeutics (SER) as of Q2 2023, unchanged from Q1 2023.
- Funds reported $4.24M of Serina Therapeutics stock for Q2 2023, up 34% quarter-over-quarter.
- 2 funds opened new Serina Therapeutics positions in Q2 2023 and 2 closed out, a net change of 0 holders.
- The largest Serina Therapeutics buyer in Q2 2023 was Susquehanna International Group, an estimated $7.94K added.
- The largest Serina Therapeutics seller in Q2 2023 was Bridgeway Capital Management, an estimated $15.2K sold.
Based on aggregated 13F filings for Q2 2023.